MeSH tree: D12.776.124.486.485.114.224.060.875
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute ...
Jun 27, 2024
0
50
Combining two cancer drugs may be a promising treatment for advanced metastatic breast cancer, according to the results of a clinical trial published in JAMA Oncology.
Jun 17, 2024
0
58
Monoclonal antibodies are crucial therapeutics due to their high specificity and binding affinity for epitopes (the precise sites where an antibody attaches itself to an antigen, triggering an immune response). Since the ...
Jun 10, 2024
0
26
Research recently published in Drug Resistance Updates has revealed a previously unknown biological process through which breast tumor cells develop resistance to standard treatment, which could open the door for cancer scientists ...
May 29, 2024
0
44
A new meta-analysis published in OMICS: A Journal of Integrative Biology helps shed light on how changes in mitochondria-related gene expression may cause the cardiotoxicity associated with the cancer therapy trastuzumab.
Mar 18, 2024
0
44
In a new paper published in Cancer Research, researchers at MUSC Hollings Cancer Center have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can restore the effectiveness ...
Feb 6, 2024
0
41
Choosing the right cancer treatment is a massive undertaking involving multiple stages, high experimental complexity and significant costs. Currently, two main methods are used to find the best possible treatment solutions: ...
Jan 16, 2024
0
20
A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast ...
Dec 6, 2023
0
34
Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the ...
Nov 8, 2023
0
59
For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and trastuzumab, according to a study published online Oct. ...
Oct 25, 2023
0
42
